MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product D...(ng formulations asdifferentiators from g...),Health

Date:8/4/2008

ng formulations as differentiators from generic entrants. We also believe that our PharmFilm(R) technology offers an attractive opportunity to extend product revenue life-cycles. The validity of our technology has been established by our over the counter drug product introductions and other prescription pharmaceutical partnerships, including the recently announced licensing of our thin film formulation of ondansetron, an anti-emetic therapy, to Strativa Pharmaceuticals, a division of Par Pharmaceuticals. Our expectation is to partner our PharmFilm(R) escitalopram oxalate product with a pharmaceutical company that is competitively positioned in this market."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver drugs in quick dissolving films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of currently marketed drugs. The Company is a leader in thin film drug delivery and has a strong intellectual property position, a portfolio of commercialized OTC drug products, and a pipeline of prescription formulations utilizing its PharmFilm(R) technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that enable the funding of prescription product development programs that will generate long-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator or other specialty pharma or leading consumer products companies who have the core competency to sell-in and manage the sales and marketing of the products. For the Company's existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differenti
'/>"/>

SOURCE MonoSol Rx Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
2. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
3. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
4. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
5. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
6. Pulmo BioTech Inc. Completes Bio-Distribution Studies
7. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
8. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
9. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
10. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
11. Pharmaxis Long-Term Safety Study of Bronchitol Completes